The Company of Biologists

Table 1.

Neural induction by BMP inhibition requires intact FGFR signalling in animal caps

Assay	n	% NCAM>0
Untreated cap + Noggin (stage 10.25)^{^*}	38	50
SU cap + Noggin (stage 10.25)^{^*}	36	0
Untreated cap + Noggin (stage 9)^{^†}	22	55
Untreated cap + Noggin + SU (stage 9)^{^†}	21	0
Untreated cap + Noggin (stage 10)^{^†}	40	60
Untreated cap + Noggin + SU (stage 10)^{^†}	38	3
Smad6 cap^{^‡}	13	100
Smad6 cap^{^‡} + SU(stage 13)	16	0

Assay	n	% NCAM>0
Untreated cap + Noggin (stage 10.25)^{^*}	38	50
SU cap + Noggin (stage 10.25)^{^*}	36	0
Untreated cap + Noggin (stage 9)^{^†}	22	55
Untreated cap + Noggin + SU (stage 9)^{^†}	21	0
Untreated cap + Noggin (stage 10)^{^†}	40	60
Untreated cap + Noggin + SU (stage 10)^{^†}	38	3
Smad6 cap^{^‡}	13	100
Smad6 cap^{^‡} + SU(stage 13)	16	0

DMZ, dorsal marginal zone; cap, animal cap.

1 μg/ml Noggin protein was added to animal caps pre-treated or not with 80 μM SU5402

Untreated animal caps were cultured with 1 μg/ml Noggin protein in the presence or not of 80 μM SU5402

See legend to Fig. 7